Brain-derived neurotrophic factor (BDNF) is the most prevalent neurotrophin in brain;via actions on its high affinity trkB receptor it enhances the survival of many types of central neurons and is implicated in several forms of neural plasticity in the brain. Recent work suggests that endogenous BDNF in the hippocampus may be involved in mediating antidepressant responses, in depression models in mice. A rather surprising finding in the field of depression has been the demonstration that ketamine, an ionotropic glutamatergic n-methyl-daspartate (NMDA) receptor antagonist, has rapid and long-lasting antidepressant effects in depressed individuals. We have started to investigate the mechanisms of the antidepressant activity of ketamine, specifically the potential involvement of endogenous BDNF in the hippocampus. In preliminary experiments, we find that the NMDA receptor antagonists, ketamine, MK801 or CPP, produce fast-acting antidepressant behavioral effects in depression models in mice. The fast acting antidepressant effects of ketamine occurs via a BDNF dependent manner because these effects are lost in forebrain specific BDNF knockout mice. Our findings also suggest that the antidepressant effects of ketamine require protein translation, but not transcription, resulting in increases in BDNF protein levels that are important for the behavioral effect. Recent work has suggested a strong causal link between blockade of resting NMDA receptor activation and rapid increases in local dendritic protein translation. In agreement with recent in vitro work, we find that ketamine causes a decrease in phosphorylation of eukaryotic elongation factor 2 (eEF2), which normally impedes translation in its phosphorylated state, suggesting translational de-repression of BDNF mRNA. Importantly, we provide preliminary evidence that inhibitors of the eEF2 kinase (also called CaMKIII) that normally phosphorylates eEF2 trigger a fast-acting antidepressant-like effect in depression models in mice. These findings suggest a behavioral and clinically relevant correlate of dendritic translational de-repression by NMDA receptors. The objective of this grant is to link the regulation of translational repression to the effects of antidepressants. Collectively, these studies promise to provide fundamentally novel information concerning how endogenous BDNF in the hippocampus is involved in the fast acting antidepressant response of ketamine and offer new leads toward the development of faster acting antidepressants.
The objective of this grant is to study the role of BDNF in the hippocampus in mediating antidepressant responses in mice. Based on our preliminary data presented in this application, we will examine the role of the eEF2 signaling pathway in mediating fast acting antidepressant responses upstream of BDNF. These studies will use molecular, cellular and behavioral approaches to investigate the the signaling pathways involved in mediating fast acting antidepressant responses, in the hopes of developing faster acting antidepressants.
|Horvath, Patricia M; Monteggia, Lisa M (2018) MeCP2 as an Activator of Gene Expression. Trends Neurosci 41:72-74|
|Monteggia, Lisa M; Lin, Pei-Yi; Adachi, Megumi et al. (2018) Behavioral Analysis of SNAP-25 and Synaptobrevin-2 Haploinsufficiency in Mice. Neuroscience :|
|Horvath, Patricia M; Kavalali, Ege T; Monteggia, Lisa M (2017) CRISPR/Cas9 system-mediated impairment of synaptobrevin/VAMP function in postmitotic hippocampal neurons. J Neurosci Methods 278:57-64|
|Adachi, Megumi; Autry, Anita E; Mahgoub, Melissa et al. (2017) TrkB Signaling in Dorsal Raphe Nucleus is Essential for Antidepressant Efficacy and Normal Aggression Behavior. Neuropsychopharmacology 42:886-894|
|Ramirez, Denise M O; Crawford, Devon C; Chanaday, Natali L et al. (2017) Loss of Doc2-Dependent Spontaneous Neurotransmission Augments Glutamatergic Synaptic Strength. J Neurosci 37:6224-6230|
|Crawford, Devon C; Ramirez, Denise M O; Trauterman, Brent et al. (2017) Selective molecular impairment of spontaneous neurotransmission modulates synaptic efficacy. Nat Commun 8:14436|
|Björkholm, Carl; Monteggia, Lisa M (2016) BDNF - a key transducer of antidepressant effects. Neuropharmacology 102:72-9|
|Monteggia, Lisa M (2016) Toward Better Animal Models for Molecular Psychiatry. Biol Psychiatry 79:2-3|
|Kavalali, Ege T; Monteggia, Lisa M (2015) How does ketamine elicit a rapid antidepressant response? Curr Opin Pharmacol 20:35-9|
|Monteggia, Lisa M; Zarate Jr, Carlos (2015) Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol 30:139-43|
Showing the most recent 10 out of 39 publications